Skip to main content
Neovacs logo

Neovacs — Investor Relations & Filings

Ticker · ALNEV ISIN · FR001400MV37 LEI · 9695001J9GMM5XYK6482 Euronext Growth Professional, scientific and technical activities
Open in API
Filings indexed 455 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country FR France
Listing Euronext Growth ALNEV

About Neovacs

https://www.neovacs.com/en/

Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.

Recent filings

Filing Released Lang Actions
Néovacs a présenté son expertise unique lors de la 2ème rencontre française sur les NanoParticules Lipidiques (LNPs) pour la délivrance d'ARN
Regulatory Filings Classification · 95% confidence The document is a press release announcing Néovacs' participation in a scientific event related to lipid nanoparticles for RNA delivery. It describes the company's activities and expertise, mentions financing instruments and potential dilution risks, but does not contain any financial statements, detailed financial results, or regulatory filings. It is a communication aimed at investors and the public about the company's scientific and financing context, not a formal financial report or regulatory filing. The document length is under 5,000 characters and reads like a press release rather than a detailed report. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement and communication that does not fit other specific categories.
2026-05-19 French
Regroupement des actions Néovacs, suspension de la faculté d'exercice des valeurs mobilières donnant accès au capital de la Société et ajustement du calendrier de tirage sur la ligne de financement
Capital/Financing Update Classification · 95% confidence The document is a press release from Néovacs announcing a share consolidation (reverse stock split) and suspension of exercise rights on securities giving access to the company's capital. It details the terms of the share consolidation, dates, ISIN codes, and the impact on shareholders. It also mentions adjustments to the financing drawdown schedule. The document is an announcement of a capital structure change (share consolidation) and financing update, not a full financial report or earnings release. It is not a regulatory filing or report publication announcement since it contains substantive information about the capital change and financing schedule. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-05-06 French
L'agence nationale de la recherche (ANR) met en lumière le programme ARNm IgE 'AllergyVacs2' à l'occasion de la semaine Européenne de la vaccination.
Regulatory Filings Classification · 95% confidence The document is a press release from Néovacs highlighting a research program funded by the French National Research Agency (ANR). It discusses the scientific and funding aspects of a vaccine development project but does not contain any financial statements, regulatory filings, or detailed financial results. It is not an earnings release, annual report, or any formal regulatory filing. The document is a communication about a research program and funding, typical of a press release or announcement. Given the content and length (under 5,000 characters), it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2026-05-05 French
Résultats annuels 2025
Annual Report Classification · 95% confidence The document is a press release presenting the annual financial results for the year 2025 of Néovacs, including detailed financial performance data such as operating results, net results, cash position, equity, and debt. It also discusses strategic decisions, cost optimization, and capital adjustments. The document mentions that the annual financial report is available on the company's website and that the accounts have been certified by auditors. The length of the document (7356 characters) and the presence of substantive financial data and analysis indicate this is the actual annual report content rather than a mere announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-30 French
Le projet VECT-PI sélectionné pour un financement dans le cadre de France 2030
Capital/Financing Update Classification · 85% confidence The document is a press release by Neovacs announcing that its VECT-PI project has been officially selected for a €2 million funding grant under the France 2030 program. It discusses financing arrangements and grant funding rather than publishing financial results, regulatory filings, or corporate governance changes. This is an update on the company’s financing activity (receipt of grant funding), which fits the Capital/Financing Update category.
2026-04-29 French
Information relative au nombre total de droits de vote et d'actions composant le capital social
Share Issue/Capital Change Classification · 85% confidence The document is a press release by the company disclosing the total number of shares and voting rights composing its share capital, as well as monthly issuances from convertible securities (OCEANE, ORA/OS, BSAE). It is not a financial report, call transcript, or AGM materials, but rather an announcement of changes in share capital. This falls under “Share Issue/Capital Change” (SHA).
2026-04-15 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.